Benzothiophene inhibitors of MK2. Part 2: improvements in kinase selectivity and cell potency.
Anderson, D.R., Meyers, M.J., Kurumbail, R.G., Caspers, N., Poda, G.I., Long, S.A., Pierce, B.S., Mahoney, M.W., Mourey, R.J., Parikh, M.D.(2009) Bioorg Med Chem Lett 19: 4882-4884
- PubMed: 19616942 
- DOI: https://doi.org/10.1016/j.bmcl.2009.02.017
- Primary Citation of Related Structures:  
3FYJ, 3FYK, 3FZ1 - PubMed Abstract: 
Optimization of kinase selectivity for a set of benzothiophene MK2 inhibitors provided analogs with potencies of less than 500 nM in a cell based assay. The selectivity of the inhibitors can be rationalized by examination of X-ray crystal structures of inhibitors bound to MK2.
Organizational Affiliation: 
Pfizer Global Research and Development, St Louis Laboratories, Chesterfield, MO 63017, USA. david.r.anderson@pfizer.com